AP 12009 TGF-beta2 antisense oligonucleotide regulatory update

The FDA granted Orphan Drug designation to Antisense's AP 12009 to treat malignant glioma. The product, which is in Phase I/II testing in Europe, also received Orphan Drug designation from the EMEA (s...